Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesDynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
Cancer, 06/15/09
Quintás-Cardama A et al. – Study reports that hematologic toxicity was frequent during dasatinib therapy in patients with chronic myeloid leukemia in chronic phase (CP CML), particularly at doses >100 mg daily. Treatment interruption and/or dose reduction as well as growth factor support were safe and efficacious strategies to facilitate the continuous administration of dasatinib.
Methods- Aim was to investigate the incidence, dynamics, and management of cytopenias in ps with CP CML who received dasatinib therapy after imatinib failure
- Data were analyzed from 130 pts in phase 1 (n=22) or phase 2 or 3 (n=108) studies for grade 2 to 4 cytopenia
- Grade 2 to 4 neutropenia and/or thrombocytopenia occurred in 94 (72%) pts during dasatinib therapy
- Grade 3 to 4 occurred in 67 (52%) pts
- Of the 94 pts who developed grade 2 to 4 neutropenia and/or thrombocytopenia-
- 68% also developed at least grade 2 anemia, and
- 17% grade 3 to 4 anemia
- Management of cytopenias included:
- Transient dasatinib interruption in 35 (37%) pts
- Filgrastim in 12 (14%) pts
- Recombinant erythropoietin in 29 (45%) pts, and
- Interleukin-11 in 3 (5%) pts
- Factors associated with an increased risk for developing grade 2 to 4 cytopenias were:
- Longer time from diagnosis to treatment
- Prior interferon or imatinib therapy, and
- Lower white blood cell count at the initiation of dasatinib therapy
- 68% also developed at least grade 2 anemia, and
Related Articles
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP
Blood, 10/09/09
Relevance Score: 82%
Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation
Blood, 11/06/09
Relevance Score: 81%
SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of chronic myeloid leukemia
Genes, Chromosomes and Cancer, 10/28/09
Relevance Score: 81%
Novartis drug Tasigna meets primary endpoint in pivotal trial against Glivec as first-line treatment in chronic myeloid leukemia patients
Novartis, 10/21/09
Relevance Score: 81%
Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Blood, 10/02/09
Relevance Score: 81%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI)
Journal of Hematology & Oncology, 11/25/09
Association between defb1 gene haplotype and herpes viruses seroprevalence in children with acute lymphoblastic leukemia
Pediatric Hematology and Oncology, 11/25/09
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909
Journal of Clinical Oncology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial
British Journal of Cancer, 11/29/09
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer
Cancer, 11/25/09
Incidence of oral mucositis, its treatment and pain management in patients receiving cancer treatment at Radiation Oncology Departments in Spanish hospitals (MUCODOL Study)
Clinical and Translational Oncology, 11/25/09
Hemorrhagic Gastritis and Duodenitis Following Celiac Plexus Neurolysis
Pain Physician, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor